Skip to main content
Fig. 1 | BMC Pediatrics

Fig. 1

From: Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan

Fig. 1

Overview of the study design. CAI Clinical Activity Index, IFX infliximab. CAI score-based responder: patient who had a decreased (improved) CAI score at Week 8 compared with that measured at the time of registration. CAI score-based non-responder: patient who had an unchanged or increased (worsened) CAI score at Week 8 compared with that measured at the time of registration

Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us